June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
The Effect of Cyclosporine A In Pterygium Surgery With Fibrin Glue
Author Affiliations & Notes
  • Güldeniz Usta
    Ophthalmology, Istanbul Universitesi-Cerrahpasa, Istanbul, Istanbul, Turkey
  • Ceyhun ARICI
    Ophthalmology, Istanbul Universitesi-Cerrahpasa, Istanbul, Istanbul, Turkey
  • Footnotes
    Commercial Relationships   Güldeniz Usta None; Ceyhun ARICI None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2937. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Güldeniz Usta, Ceyhun ARICI; The Effect of Cyclosporine A In Pterygium Surgery With Fibrin Glue. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2937.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effect of topical cyclosporine A (CsA) 0.05% (Depores, Deva, Turkey) in patients with pterygium surgery using fibrin glue (Tisseel, Baxter Healthcare Corp., USA)

Methods : A total of 80 eyes with primary pterygium (74 patients) were divided into two groups. Group 1 (41 eyes of 35 patients) was the control group which received a combined antibiotic and steroid eye drop (Moxidexa, Abdi Ibrahim, Turkey) and artificial tear drop (Thealoz duo, Théa, France) for 28 postoperative days. Group 2 (39 eyes of 33 patients) was the CsA group that received topical 0.05% CsA twice a day for 6 months postoperatively, in addition to the same combination of an antibiotic and steroid eye drop and artificial tear that was used for the control group. Pterygium recurrence was defined as regrowth of fibrovascular tissue onto the clear cornea, in the region of previous pterygium removal. Detailed ophthalmic examination were done in all patients. The patients were evaluated for recurrence rate, tear film, side effects and complications at postoperative 1 and 7 days, 1st, 3rd, 6th and 12 months.

Results : The 2 groups were age and sex matched.Subconjunctival hemorrhage in graft tissue and graft retraction were seen in 2 patients in group 1 and 2.Cyclosporine drop was discontinued in one patient due to burning sensation and conjunctival hyperemia following one week usage. The average preoperative Schirmer I and fluorescein break-up time (BUT) values of the group 1 were 10.0±2.37 mm and 8.46±2.16 s.At the end of 12 months postoperatively, the average Schirmer I was 10.39±1.99 mm and BUT was 8.85±1.98 s (both p>0.05).Preoperative mean Schirmer I and BUT test results of the patients in group 2 was 9.62±2.65 mm and 9.08±2.46 s.At the end of 12 months, while the average Schirmer I value was 10.62±2.55 mm (p<0.05), the average BUT value was 9.38±2.00 s (p>0.05). When preoperative and postoperative Schirmer I and BUT test results were compared, there was no statistically significant difference between group 1 and 2. Recurrence was observed in only one patient from group 1, no recurrence was seen in group 2, but it was not statistically significant.

Conclusions : Although no statistically significant difference was seen in terms of recurrence between group 1 and 2, no recurrence was seen in CsA group. CsA usage may increase the success rate.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

The Control Group A-Preoperative B-Postoperative 1 year

The Control Group A-Preoperative B-Postoperative 1 year

 

The CsA Group A-Preoperative B-Postoperative 1 year

The CsA Group A-Preoperative B-Postoperative 1 year

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×